Literature DB >> 30826455

RGS2 promotes the translation of stress-associated proteins ATF4 and CHOP via its eIF2B-inhibitory domain.

Chang-Hui Jenny Wang1, Peter Chidiac2.   

Abstract

Regulator of G protein signaling 2 (RGS2) is upregulated by multiple forms of stress and can augment translational attenuation associated with the phosphorylation of the initiation factor eIF2, a hallmark of several stress-induced coping mechanisms. Under stress-induced translational inhibition, key factors, such as ATF4, are selectively expressed via alternative translation mechanisms. These factors are known to regulate molecular switches that control cell fate by regulating pro-survival and pro-apoptotic signals. The molecular mechanisms that balance these opposing responses to stresses are unclear. The present results suggest that RGS2 may be an important regulatory component in the cellular stress response through its translational control abilities. Previously, we have shown that RGS2 can interact with the translation initiation factor, eIF2B, and inhibit de novo protein synthesis. Here, we demonstrate that the expression of either full length RGS2 or its eIF2B-interacting domain (RGS2eb) significantly increases levels of ATF4 and CHOP, both of which are linked to stress-induced apoptosis. Furthermore, we show that these effects are translationally regulated and independent of eIF2 phosphorylation. The present results thus point to a novel function of RGS2 in the stress response directly related to its ability to reduce global protein synthesis.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  ATF4; CHOP; Cell stress response; Eukaryotic initiation factor 2 (eIF2); Regulator of G protein signaling 2 (RGS2); Translation

Year:  2019        PMID: 30826455     DOI: 10.1016/j.cellsig.2019.02.007

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  6 in total

Review 1.  Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials.

Authors:  Joseph B O'Brien; Joshua C Wilkinson; David L Roman
Journal:  J Biol Chem       Date:  2019-10-21       Impact factor: 5.157

2.  RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse.

Authors:  Jaebeom Cho; Hye-Young Min; Ho Jin Lee; Seung Yeob Hyun; Jeong Yeon Sim; Myungkyung Noh; Su Jung Hwang; Shin-Hyung Park; Hye-Jin Boo; Hyo-Jong Lee; Sungyoul Hong; Rang-Woon Park; Young Kee Shin; Mien-Chie Hung; Ho-Young Lee
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

3.  The Increased Expression of Regulator of G-Protein Signaling 2 (RGS2) Inhibits Insulin-Induced Akt Phosphorylation and Is Associated with Uncontrolled Glycemia in Patients with Type 2 Diabetes.

Authors:  J Gustavo Vazquez-Jimenez; M Stephanie Corpus-Navarro; J Miguel Rodriguez-Chavez; Hiram J Jaramillo-Ramirez; Judith Hernandez-Aranda; Octavio Galindo-Hernandez; J Rene Machado-Contreras; Marina Trejo-Trejo; Agustin Guerrero-Hernandez; J Alberto Olivares-Reyes
Journal:  Metabolites       Date:  2021-02-05

4.  Bioactive glass selectively promotes cytotoxicity towards giant cell tumor of bone derived neoplastic stromal cells and induces MAPK signalling dependent autophagy.

Authors:  Joerg Fellenberg; Sarina Losch; Burkhard Lehner; Marcela Arango-Ospina; Aldo R Boccaccini; Fabian Westhauser
Journal:  Bioact Mater       Date:  2022-02-28

5.  Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer.

Authors:  Jana Ihlow; Nanna Monjé; Inga Hoffmann; Philip Bischoff; Bruno Valentin Sinn; Wolfgang Daniel Schmitt; Catarina Alisa Kunze; Sylvia Darb-Esfahani; Hagen Kulbe; Elena Ioana Braicu; Jalid Sehouli; Carsten Denkert; David Horst; Eliane Tabea Taube
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

6.  Biomarker discovery in attention deficit hyperactivity disorder: RNA sequencing of whole blood in discordant twin and case-controlled cohorts.

Authors:  Timothy A McCaffrey; Georges St Laurent; Dmitry Shtokalo; Denis Antonets; Yuri Vyatkin; Daniel Jones; Eleanor Battison; Joel T Nigg
Journal:  BMC Med Genomics       Date:  2020-10-28       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.